Avutometinib and Defactinib for brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed glioblastoma or a similar high-grade brain tumor (WHO grade 4).
- You are at least 16 years old and able to care for yourself (WHO performance status 0-1).
- Your blood counts, liver, and kidney function are within safe ranges.
- You have not had certain prior treatments like immune therapy or BRAF/MEK inhibitors.
- You are not taking medications that interact with the study drugs and have no serious eye, lung, or heart conditions.
- You agree to use effective birth control during and for 150 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral medications for people who have just been diagnosed with a high-grade brain tumor. The goal is to see if the treatment is safe and feasible when given alongside standard radiation therapy.
This trial tests two oral drugs, avutometinib and defactinib, for people with a specific type of stomach cancer called diffuse gastric cancer. The goal is to see if these drugs can help shrink or slow the cancer.
This trial tests a combination of two or three drugs (defactinib, avutometinib, with or without encorafenib) to shrink brain tumors that started from skin melanoma. It may be an option for people whose melanoma has a specific genetic change and who have already tried immunotherapy.
This trial tests two oral drugs (avutometinib and defactinib) for people with certain types of advanced thyroid cancer that have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Hear when a new Glioblastoma Multiforme (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.